切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2016, Vol. 05 ›› Issue (01) : 10 -13. doi: 10.3877/cma.j.issn.2095-3216.2016.01.003

所属专题: 文献

专家论坛

慢性肾脏病患者高尿酸血症的管理
李英1()   
  1. 1. 050081 石家庄,河北医科大学第三医院肾内科、河北省肾脏病研究中心
  • 收稿日期:2015-12-16 出版日期:2016-02-28
  • 通信作者: 李英

Management of hyperuricemia in patients with chronic kidney disease

Ying Li1,()   

  1. 1. Department of Nephropathy, Hebei Medical University Affiliated Third Hospital, Hebei Province Kidney Disease Research Center, Shijiazhuang 050081, Hebei, China
  • Received:2015-12-16 Published:2016-02-28
  • Corresponding author: Ying Li
  • About author:
    Corresponding author: Li Ying, Email:
引用本文:

李英. 慢性肾脏病患者高尿酸血症的管理[J]. 中华肾病研究电子杂志, 2016, 05(01): 10-13.

Ying Li. Management of hyperuricemia in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(01): 10-13.

生理情况下,人体每日尿酸的产生和排泄基本上保持动态平衡。若血清尿酸水平男>420 μmol/L,女>360 μmol/L则称为高尿酸血症。随着居民生活方式、饮食结构的改变以及人口老龄化,高尿酸血症的发病率呈逐年上升趋势。越来越多的研究表明高尿酸血症与慢性肾脏病(CKD)的关系密切。尿酸是嘌呤核苷酸代谢中不易溶解的循环终产物,CKD患者肾小球滤过率降低时,高尿酸血症发生的风险增加,而长期的高尿酸血症会导致肾功能的进行性恶化,增加患者心血管疾病的发生风险及死亡率。因此做好CKD患者高尿酸血症的管理具有重要的临床意义。关于高尿酸血症诊断和治疗有多项专家共识和指南,即改善生活方式是治疗的基础,早期干预和综合管理是治疗的核心。

Under the physiological condition, human daily production and excretion of uric acid are maintained basically at a dynamic balance.When serum uric acid level is higher than 420 μmol/L in men or 360 μmol/L in women, there is hyperuricemia. With the change of life style, diet structure, and increase of aging population, the incidence of hyperuricemia is increasing year by year. Recently more and more researches have indicated that hyperuricemia is closely related to chronic kidney disease (CKD). Uric acid is the poorly soluble circulating end product of the purine nucleotide metabolism. A reduction in the glomerular filtration rate (GFR) contributes to hyperuricemia. Long- term hyperuricemia can lead to progressive deterioration of renal function, increasing the risk of cardiovascular disease in patients with increased mortality. It is important to investigate the management for CKD patients with hyperuricemia. There are expert consensus and guidelines for diagnosis and treatment of the hyperuricemia. The basis of treatment is improving the life style, and the core of treatment are early intervention and comprehensive management.

1
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross- sectional survey [J]. Lancet, 2012, 379(9818): 815-822.
2
Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end- stage renal disease: 25- year follow- up [J]. Arch Intern Med, 2009, 169(4): 342-350.
3
Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease [J]. J Am Soc Nephrol, 2008, 19(12): 2407-2413.
4
Kim WJ, Kim SS, Bae MJ, et al. High- normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function [J]. J Diabetes Complications, 2014, 28(2): 130-134.
5
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
6
Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes [J]. J Diabetes Complications, 2014, 28(2): 124-129.
7
Prasad SO, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review [J]. Nephrourol Mon, 2015, 7(3): e27233.
8
Wang S, Chen R, Liu Q, et al. Prevalence, awareness and treatment of chronic kidney disease among middle- aged and elderly: the China health and retirement longitudinal study [J]. Nephrology (Carlton), 2015, 20(7): 474-484.
9
Yang B, Mo Z, Wu C, et al. A genome- wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population [J]. BMC Med Genomics, 2014, 7: 10.
10
Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family- based study [J]. Am J Kidney Dis, 2015, 65(2): 294-302.
11
Kumral E, Karaman B, Orman M, et al. Association of uric acid and carotid artery disease in patients with ischemic stroke [J]. Acta Neurol Scand, 2014, 130(1): 11-17.
12
唐湘玲,陈梦颖,张卫茹. 慢性肾脏病患者血清内脏脂肪素水平升高及其与颈动脉粥样硬化的关系[J].中南大学学报(医学版), 2013,38(6): 554-559.
13
Bao X, Wang Q, Chen G, et al. Serum concentration of uric acid associated with prehypertension among Chinese population [J]. Angiology, 2014, 65(9): 800-805.
14
Liu YL, Pan Y, Wang X, et al. Betaine reduces serum uric acid levels and improves kidney function in hyperuricemic mice [J]. Planta Med, 2014, 80(1): 39-47.
15
Cai G, Zheng Y, Sun X, et al. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in China [J]. J Am Geriatr Soc, 2013, 61(12): 2160-2167.
16
中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志,2013,29(11): 913-920.
17
Hamburger M, Baraf HS, Adamson TR, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia [J]. Phys Sportsmed, 2011, 39(4): 98-123.
18
Soltani Z, Rasheed K, Kapusta DR, et al. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal [J]? Curr Hypertens Rep, 2013, 15(3): 175-181.
19
Qiu L, Cheng XQ, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces [J]. BMC Public Health, 2013, 13: 664.
20
Xue C, Ye XD, Li W, et al. Prevalence of chronic kidney disease in Jing adults in China: a village- based study [J]. Clin Nephrol, 2013, 79(1): 50-56.
21
Goicoechea M, Garcia DVS, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long- term follow- up of a randomized clinical trial [J]. Am J Kidney Dis, 2015, 65(4): 543-549.
22
Bellomo G. The relationship between uric acid, allopurinol, cardiovascular events, and kidney disease progression: a step forward [J]. Am J Kidney Dis, 2015, 65(4): 525-527.
23
Park DJ, Kang JH, Lee JW, et al. Cost- effectiveness analysis of HLA- B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea [J]. Arthritis Care Res (Hoboken), 2015, 67(2): 280-287.
24
Sakai Y, Otsuka T, Ohno D, et al. Febuxostat for treating allopurinol- resistant hyperuricemia in patients with chronic kidney disease [J]. Ren Fail, 2014, 36(2): 225-231.
25
Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease [J]. J Clin Pharm Ther, 2013, 38(3): 258-261.
26
Ohno I. The cutting- edge of medicine; role of hyperuricemia in cardiorenal syndrome [J]. Nihon Naika Gakkai Zasshi, 2013, 102(6): 1484-1491.
27
Yood RA, Ottery FD, Irish W, et al. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo- controlled, phase 3 clinical trials [J]. BMC Res Notes, 2014, 7: 54.
28
Bleyer AJ, Wright D, Alcorn H. Pharmacokinetics and pharmacodynamics of pegloticase in patients with end- stage renal failure receiving hemodialysis [J]. Clin Nephrol, 2015, 83(5): 286-292.
[1] 陈舜, 薛恩生, 叶琴. PDCA在持续改进超声危急值管理制度中的价值[J]. 中华医学超声杂志(电子版), 2023, 20(09): 974-978.
[2] 江泽莹, 王安婷, 王姣丽, 陈慈, 周秋玲, 黄燕娟, 周芳, 薛琰, 周剑烽, 谭文勇, 杜美芳. 多种植物油组分预防肿瘤放化疗相关毒性反应的效果分析[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 523-527.
[3] 朴广昊, 李屹洲, 刘瑞, 赵建民, 王凌峰. 皮肤撕脱伤撕脱皮瓣活力早期评估与修复的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 528-532.
[4] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[7] 单秋洁, 孙立柱, 徐宜全, 王之霞, 徐妍, 马浩, 刘田田. 中老年食管癌患者调强放射治疗期间放射性肺损伤风险模型构建及应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 388-393.
[8] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[9] 王丽芳, 宁武, 丁艳, 张彦霞, 马豆豆, 卢哲敏, 韩芃, 李超然, 王宽婷. 北京市石景山区中学生的血尿酸与血清25(OH)D3水平的相关性研究[J]. 中华临床医师杂志(电子版), 2023, 17(08): 865-869.
[10] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[11] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[12] 易成, 韦伟, 赵宇亮. 急性肾脏病的概念沿革[J]. 中华临床医师杂志(电子版), 2023, 17(08): 906-910.
[13] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[14] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要